We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
Read MoreHide Full Article
Key Takeaways
GSK's NDA for linerixibat in cholestatic pruritus tied to PBC has been accepted by the FDA for review.
The NDA is based on GLISTEN study data showing rapid and sustained itch relief versus placebo.
If approved, linerixibat could be the first global therapy for PBC-related itch and sleep disruption.
GSK plc (GSK - Free Report) announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval of its investigational targeted inhibitor of the ileal bile acid transporter (“IBAT”), linerixibat, for treating cholestatic pruritus in patients with primary biliary cholangitis (“PBC”).
With the FDA accepting the NDA for review, a decision from the regulatory body is expected on March 24, 2026.
If approved, linerixibat could address an area of high unmet medical need for patients living with cholestatic pruritus and related sleep interference.
Year to date, shares of GSK have rallied 23.2% against the industry’s decline of 3.8%.
Image Source: Zacks Investment Research
Linerixibat NDA Based on GSK's GLISTEN Study
The NDA for linerixibat was based on data from the phase III GLISTEN study. In November 2024, the company announced positive data from the study.
The study met both the primary and key secondary endpoints, wherein treatment with linerixibat led to a rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo.
Cholestatic pruritus (relentless itch) is one of the most common symptoms of PBC, a rare autoimmune disease that might lead to liver failure.
Per management, if successfully developed, linerixibat has the potential to become the first therapy indicated for treating itch associated with PBC globally.
Other Players in the PBC Market
A few other companies are also developing treatments for PBC, as there remains a high unmet medical need.
In August 2024, the FDA granted accelerated approval to Gilead Sciences’ (GILD - Free Report) seladelpar for the treatment of PBC, in combination with ursodeoxycholic acid (“UDCA”), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
The candidate was approved under the brand name Livdelzi.
Seladelpar was added to GILD’s portfolio/pipeline through the acquisition of CymaBay Therapeutics Inc. for $4.3 billion in March 2024. The approval of Livdelzi strengthened GILD’s liver disease portfolio.
Small biotech Mirum Pharmaceuticals (MIRM - Free Report) is developing its pipeline candidate, volixibat, also an oral IBAT inhibitor, for the treatment of PBC.
The phase IIb VANTAGE study is currently evaluating MIRM’s volixibat for treating PBC.
Mirum expects to complete enrollment in the VANTAGE study in 2026.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.57 to 86 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.80 to $1.34. Year to date, shares of IMCR have rallied 31.1%.
IMCR’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
Key Takeaways
GSK plc (GSK - Free Report) announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval of its investigational targeted inhibitor of the ileal bile acid transporter (“IBAT”), linerixibat, for treating cholestatic pruritus in patients with primary biliary cholangitis (“PBC”).
With the FDA accepting the NDA for review, a decision from the regulatory body is expected on March 24, 2026.
If approved, linerixibat could address an area of high unmet medical need for patients living with cholestatic pruritus and related sleep interference.
Year to date, shares of GSK have rallied 23.2% against the industry’s decline of 3.8%.
Image Source: Zacks Investment Research
Linerixibat NDA Based on GSK's GLISTEN Study
The NDA for linerixibat was based on data from the phase III GLISTEN study. In November 2024, the company announced positive data from the study.
The study met both the primary and key secondary endpoints, wherein treatment with linerixibat led to a rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo.
Cholestatic pruritus (relentless itch) is one of the most common symptoms of PBC, a rare autoimmune disease that might lead to liver failure.
Per management, if successfully developed, linerixibat has the potential to become the first therapy indicated for treating itch associated with PBC globally.
Other Players in the PBC Market
A few other companies are also developing treatments for PBC, as there remains a high unmet medical need.
In August 2024, the FDA granted accelerated approval to Gilead Sciences’ (GILD - Free Report) seladelpar for the treatment of PBC, in combination with ursodeoxycholic acid (“UDCA”), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
The candidate was approved under the brand name Livdelzi.
Seladelpar was added to GILD’s portfolio/pipeline through the acquisition of CymaBay Therapeutics Inc. for $4.3 billion in March 2024. The approval of Livdelzi strengthened GILD’s liver disease portfolio.
Small biotech Mirum Pharmaceuticals (MIRM - Free Report) is developing its pipeline candidate, volixibat, also an oral IBAT inhibitor, for the treatment of PBC.
The phase IIb VANTAGE study is currently evaluating MIRM’s volixibat for treating PBC.
Mirum expects to complete enrollment in the VANTAGE study in 2026.
GSK's Zacks Rank & Another Key Pick
GSK currently carries a Zacks Rank #2 (Buy).
Another top-ranked stock in the biotech sector is Immunocore Holdings (IMCR - Free Report) , carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.57 to 86 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.80 to $1.34. Year to date, shares of IMCR have rallied 31.1%.
IMCR’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.